Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.
作者信息
Schore Reuven J, Angiolillo Anne L, Kairalla John A, Devidas Meenakshi, Rabin Karen R, Zweidler-McKay Patrick, Borowitz Michael J, Wood Brent, Carroll Andrew J, Heerema Nyla A, Relling Mary V, Hitzler Johann, Kadan-Lottick Nina S, Maloney Kelly, Wang Cindy, Carroll William L, Winick Naomi J, Raetz Elizabeth A, Loh Mignon L, Hunger Stephen P
机构信息
Children's National Health System, Washington, DC, USA.
George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
出版信息
Leukemia. 2023 Jun;37(6):1375-1378. doi: 10.1038/s41375-023-01870-8. Epub 2023 Mar 25.
Abstract
摘要
相似文献
1
Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.低强度方案治疗低危B淋巴细胞白血病患儿疗效显著：儿童肿瘤协作组AALL0932研究报告
Leukemia. 2023 Jun;37(6):1375-1378. doi: 10.1038/s41375-023-01870-8. Epub 2023 Mar 25.
2
Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932.标准风险 B 淋巴细胞白血病中减少长春新碱和地塞米松脉冲治疗的频率可获得良好的结果：来自儿童肿瘤学组 AALL0932 的结果。
J Clin Oncol. 2021 May 1;39(13):1437-1447. doi: 10.1200/JCO.20.00494. Epub 2021 Jan 7.
3
[Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].[儿童高危急性淋巴细胞白血病的治疗策略]
Beijing Da Xue Xue Bao Yi Xue Ban. 2013 Apr 18;45(2):327-32.
4
Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.更正：低危B淋巴细胞白血病患儿采用两种低强度方案的卓越疗效：儿童肿瘤协作组AALL0932报告
Leukemia. 2023 Jun;37(6):1406. doi: 10.1038/s41375-023-01921-0.
5
Favorable Trisomies and Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331.低风险B细胞急性淋巴细胞白血病中有利的三体异常与治愈预测：儿童肿瘤协作组AALL0331试验结果
J Clin Oncol. 2021 May 10;39(14):1540-1552. doi: 10.1200/JCO.20.02370. Epub 2021 Mar 19.
6
Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232.按治疗组和中心水平的费用和住院日比较 III 期高危 B 急性淋巴细胞白血病试验 AALL0232 的变化。
Cancer Med. 2018 Jan;7(1):3-12. doi: 10.1002/cam4.1206. Epub 2017 Dec 23.
7
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.高 CD45 表面表达决定了按照 ALL-BFM 2000 方案治疗的前体 B 细胞和 T 细胞急性淋巴细胞白血病患儿的复发风险。
Haematologica. 2014 Jan;99(1):103-10. doi: 10.3324/haematol.2013.090225. Epub 2013 Aug 2.
8
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG.在巩固/延迟强化治疗期间用环磷酰胺/依托泊苷替代环磷酰胺/阿糖胞苷/巯嘌呤并不能改善儿童 B 细胞急性淋巴细胞白血病的预后：COG 的报告。
Haematologica. 2019 May;104(5):986-992. doi: 10.3324/haematol.2018.204545. Epub 2018 Dec 13.
9
引用本文的文献
1
Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.IKZF1基因改变的异质性与儿童B细胞前体急性淋巴细胞白血病的复发风险
Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02633-3.
2
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.博纳吐单抗用于儿童标准风险B细胞急性淋巴细胞白血病的治疗
N Engl J Med. 2025 Feb 27;392(9):875-891. doi: 10.1056/NEJMoa2411680. Epub 2024 Dec 7.
3
Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.IKZF1基因改变的异质性与儿童B细胞前体急性淋巴细胞白血病的复发风险
Res Sq. 2024 Nov 11:rs.3.rs-5292018. doi: 10.21203/rs.3.rs-5292018/v1.
4
Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia.急性淋巴细胞白血病结局的基因组决定因素。
J Clin Oncol. 2024 Oct 10;42(29):3491-3503. doi: 10.1200/JCO.23.02238. Epub 2024 Aug 9.
5
Rethinking paraneoplastic eosinophilia.重新审视副肿瘤性嗜酸性粒细胞增多症。
Haematologica. 2024 Aug 1;109(8):2385-2387. doi: 10.3324/haematol.2024.285081.
6
A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL.诱导治疗开始时单次注射聚乙二醇化天冬酰胺酶不仅能加速微小残留病清除，还能改善B系急性淋巴细胞白血病患儿的长期预后。
Cancers (Basel). 2023 Nov 23;15(23):5547. doi: 10.3390/cancers15235547.
7
Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL.推进诊断和治疗，实现儿童 ALL 的普遍治愈。
J Clin Oncol. 2023 Dec 20;41(36):5579-5591. doi: 10.1200/JCO.23.01286. Epub 2023 Oct 11.
8
Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia.儿童肿瘤学组研究蓝图：急性淋巴细胞白血病。
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30585. doi: 10.1002/pbc.30585. Epub 2023 Jul 25.
本文引用的文献
1
Favorable Trisomies and Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331.低风险B细胞急性淋巴细胞白血病中有利的三体异常与治愈预测：儿童肿瘤协作组AALL0331试验结果
J Clin Oncol. 2021 May 10;39(14):1540-1552. doi: 10.1200/JCO.20.02370. Epub 2021 Mar 19.
2
Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932.标准风险 B 淋巴细胞白血病中减少长春新碱和地塞米松脉冲治疗的频率可获得良好的结果：来自儿童肿瘤学组 AALL0932 的结果。
J Clin Oncol. 2021 May 1;39(13):1437-1447. doi: 10.1200/JCO.20.00494. Epub 2021 Jan 7.
3
Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.标准风险 B 细胞急性淋巴细胞白血病患儿的结局：儿童肿瘤学组 AALL0331 试验结果。
J Clin Oncol. 2020 Feb 20;38(6):602-612. doi: 10.1200/JCO.19.01086. Epub 2019 Dec 11.
4
Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905.随机评估延迟强化和两种儿童 B-ALL 中肠外甲氨蝶呤给药方法：儿童肿瘤学组研究 P9904 和 P9905。
Leukemia. 2020 Apr;34(4):1006-1016. doi: 10.1038/s41375-019-0642-2. Epub 2019 Nov 14.
5
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).低强度延迟强化治疗在标准风险儿童急性淋巴细胞白血病中定义为微小残留病不可检测：一项国际随机试验（AIEOP-BFM ALL 2000）的结果。
J Clin Oncol. 2018 Jan 20;36(3):244-253. doi: 10.1200/JCO.2017.74.4946. Epub 2017 Nov 17.
6
Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.基于微小残留病监测的儿童急性淋巴细胞白血病的成功治疗减少和强化：荷兰儿童肿瘤学组 ALL10 研究。
J Clin Oncol. 2016 Aug 1;34(22):2591-601. doi: 10.1200/JCO.2015.64.6364. Epub 2016 Jun 6.
7
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.儿童急性淋巴细胞白血病：通过合作取得的进展
J Clin Oncol. 2015 Sep 20;33(27):2938-48. doi: 10.1200/JCO.2014.59.1636. Epub 2015 Aug 24.
8
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine.重新定义急性淋巴细胞白血病分类：迈向检测高危急性淋巴细胞白血病并实施精准医学
Blood. 2015 Jun 25;125(26):3977-87. doi: 10.1182/blood-2015-02-580043. Epub 2015 May 21.
9
Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy.接受极低剂量蒽环类药物治疗的儿童癌症幸存者的亚临床心脏毒性。
Pediatr Blood Cancer. 2015 Jan;62(1):123-7. doi: 10.1002/pbc.25206. Epub 2014 Aug 30.
10
Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.儿童和年轻成人低危急性淋巴细胞白血病微小残留病灶定义下的治疗减少（UKALL 2003）：一项随机对照试验。
Lancet Oncol. 2013 Mar;14(3):199-209. doi: 10.1016/S1470-2045(12)70600-9. Epub 2013 Feb 7.
Zotero 插件